治疗广泛期小细胞肺癌 又一国际创新药落地乐城

Core Viewpoint - The introduction of the innovative targeted immunotherapy drug Talazoparib at Ruijin Hospital in Hainan marks a significant advancement in the treatment options for adult patients with extensive-stage small cell lung cancer in China, aligning with global standards [1] Group 1: Drug Introduction and Significance - Ruijin Hospital has successfully introduced Talazoparib, becoming the first medical institution in China to make this drug available [1] - Talazoparib is a targeted immunotherapy that focuses on DLL3, which has already received approval in countries like the United States, Japan, and the United Kingdom [1] - The drug utilizes an innovative T-cell engager design to activate T-cells to precisely target and kill tumor cells, presenting a promising treatment option for small cell lung cancer [1]